Tufts CSDD released its May/June Impact report featuring demographic under-representation in clinical trials in Europe. The report summarizes analysis of a dataset made up of 1,731 clinical trials and 943 pivotal trials—representing 446 drugs and biologics—supporting EU Commission approvals of new medicines under the Centralized Procedure between 2007 and 2019. The data were collected using EMA Annual Reports, the annexes to the Annual Reports, the Human Medicines Highlights, EudraCT, European public assessment reports and other public resources.
Highlights include the following:
Click here to go the Tufts CSDD Impact Reports page.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.